|
|
|
|
|
|
|
Mon T W Th F |
|
13 July, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
For the past few months, Ryan Cross has been talking to executives, researchers and investors in biotech about a topic we keep hearing about: secrecy. The rise of China biotech has left many in the US industry somewhat paranoid. Fearful of their drugs getting copied and their programs getting surpassed, they're saying less and less about their pipelines — sometimes even hiding them from potential investors and partners. It's a must-read story that's part of our continuing journalism about the surging China biotech industry and how the US sector is responding. |
|
|
|
Drew Armstrong |
Executive Editor, Endpoints News
@ArmstrongDrew
|
|
|
|
|
|
|
by Max Gelman
|
With the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the biopharma industry... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection
lettersaid that... | |
|
|
|
 |
|
(Illustration by Ricardo Santos) |
|
|
|
by Ryan Cross
|
Janine Sengstack believes she may have found the next big breakthrough in diabetes and obesity. Her company, Junevity, has searchedthrough hundreds of genes to... | |
|
|
|
|
|
 |
|
|
|
by Kyle LaHucik
|
Apnimed is finally going forward with an IPO attempt after years of flirting with the milestone. The Cambridge, MA-based biotech revealed its Nasdaq planson... | |
|
|
|
|
|
|
by Zachary Brennan
|
The FDA on Friday posted 14 new rejection letters to pharma companies online, days after HHS confirmed to Endpoints Newsthat the agency had paused... | |
|
|
|
|
|
